Aims: Patients who have undergone Roux-en-Y gastric bypass surgery (GB) have exaggerated postprandial insulin secretion, which has been attributed to increased meal glucose appearance and enhanced incretin effect. Here, we sought to determine β-cell glucose sensitivity in the absence of meal stimulation and insulinotropic gut factors.
| INTRODUCTION
The use of bariatric surgery has steadily increased in the USA in response to the rising prevalence of obesity. Added impetus for procedures such as gastric bypass (GB) arises from the now clear benefits for glycaemic control in patients with type 2 diabetes. [1] [2] [3] Weight loss following GB leads to substantial improvement in insulin sensitivity, [4] [5] [6] but there is also considerable evidence that surgical rerouting of nutrients through the gastrointestinal (GI) tract also improves post-meal insulin secretion in diabetic and non-diabetic individuals. [7] [8] [9] [10] The mechanisms connecting surgical changes in the gut and β-cell function are not understood, but are a potential source of new targets for therapeutic development.
Assessment of prandial insulin secretion in GB subjects is complicated by increased rates of GI glucose appearance after surgery. 9, 10 Individuals with GB have substantially earlier and higher peaks of glucose after meal ingestion. 11 Along with wider prandial glycaemic excursion, GB subjects have a massive release of the incretin glucagon like-peptide 1 (GLP-1) that is also shifted earlier in the postprandial course. 11 Indeed, GB increases the incretin effect in both diabetic and non-diabetic individuals, 12, 13 and the effect of GLP-1 to stimulate insulin release increases more than 2-fold. 13 Modelling of plasma Cpeptide concentrations in GB subjects after meals also suggests increased β-cell sensitivity to glucose. 7, [14] [15] [16] However, the complexity of insulinotropic stimuli in surgical patients makes attribution of factors controlling insulin secretion difficult.
The aim of this study was to examine β-cell glucose sensitivity in GB subjects in the fasting state when the effect of meal stimulation or insulinotropic GI factors on insulin secretion is absent. We hypothesized that subjects who have undergone GB would have greater insulin responses to intravenous (IV) glucose-induced hyperglycaemia than a matched control group.
| MATERIALS AND METHODS

| Subjects
A total of 12 patients with a previous history of GB and 7 obese control subjects with no previous history of GI surgeries (CN) were recruited, in order of their presentation to clinic or their response to advertisement. Both groups had a larger ratio of female to male participants, similar to the background population of individuals with bariatric surgeries. 17 The GB individuals had fasting glucose levels less than 100 mg/dL and glycated haemoglobin (HbA1c) levels less than 5.7%, and were enrolled at least 2 years after surgery when they had been weight stable for at least 6 months. Among 12 patients after GB, 1 had a history of well controlled type 2 diabetes treated with metformin without any related complication before surgery, and this resolved completely after surgery (9 years prior to the study).
None of the GB subjects were using anti-diabetic medications or drugs that affect glucose metabolism. The GB subjects achieved an average weight loss of 57 AE 8 kg (19-100 kg) over 6 to 12 months after surgery and an average weight loss of 57 AE 7 kg (8-82 kg) over a mean of 6 AE 1 year(s) (2-11 years) since surgery. The control subjects had no personal or family history of diabetes and had normal oral glucose tolerance tests before enrollment. Both GB and CN groups were matched for age, BMI and fat mass. None of the subjects had renal dysfunction or liver disorders. The institutional review board of the University of Cincinnati approved the protocol, and all participants provided written informed consent before the studies.
| Experimental protocols
Subjects were instructed to follow their typical dietary habits and not engage in more than their usual physical activity for 3 days before each visit. Participants were admitted to the General Clinical
Research Center at Cincinnati Children's Hospital or the Clinical
Research Unit at Cincinnati VA Medical Center in the morning after an overnight fast. Body composition was assessed using dual-energy X-ray absorptiometry and waist circumference was measured by a single staff member using a standardized procedure. Intravenous catheters were placed in each forearm for the withdrawal of blood and the infusion of 20% glucose; the arm used for blood sampling was continuously warmed to facilitate blood flow.
After removal of fasting blood samples, a graded glucose infusion was started at time 0 and followed scheduled increasing and decreasing rates (0, 4, 8, 16, 8, 4 , 0 mg/kg/min) at 40-minute intervals ( Figure 1A) . Thus, the first half of the experiment (40-160 minutes) achieved a progressive step-up in blood glucose, while the second half (160-280 minutes) resulted in a gradual step-down. Blood samples were taken frequently every 5 to 10 minutes throughout the study (Figure 1 ), immediately placed on ice, and plasma was separated within 60 minutes for storage at −80 C until assay.
| Assays
Blood samples were collected in tubes containing heparin for determinations of plasma insulin and blood glucose. Blood was also collected in tubes containing 50 mM EDTA plus 500 kallikrein inhibitory units/mL aprotinin for measurement of plasma C-peptide. Blood glucose concentrations were determined at the bedside using an automated glucose analyser (YSI 2300 STAT Plus, Yellow Springs, Ohio).
Insulin concentrations were determined using commercial ELISA (Alpco, Salem, New Hampshire), and C-peptide by commercial radioimmunoassay (Millipore, Billerica, Massachusetts), each according to the manufacturers' specifications.
| Calculations and analysis
Fasting values of blood glucose and hormones were computed as the average of samples drawn from −15 to 40 minutes before initiation of the glucose infusion. Insulin secretion rates (ISR) were derived from plasma C-peptide concentrations using deconvolution with population estimates of C-peptide. 18 An assumption underlying this analysis is that gastric bypass does not affect C-peptide kinetics. Separate ISR:glucose slopes for the step-up and step-down portions of the protocol were generated for each individual using linear regression.
Data were also fitted using the minimal model, as previously described for the graded glucose protocol, to measure insulin sensitivity and glucose effectiveness. 19, 20 Glucose, insulin and ISR values during the graded glucose infusion were used to compute incremental areas under the curve (AUC) using the trapezoidal rule and are presented for the time periods 
| Statistical analysis
Data are presented as Mean AE SEM. Baseline characteristics were compared using ANOVA or Chi-square tests. The parameters obtained from each subject in the studies were compared among the 2 groups using ANOVA. Statistical analyses were performed using SPSS 23 (SPSS Inc., Chicago, Illinois).
3 | RESULTS
| Characteristics of study subjects
The groups of GB subjects and non-surgical subjects had comparable age, BMI, body composition and waist circumference ( Table 1 ). The control subjects had a similar gender distribution and similar HbA1c levels.
| Glucose levels during graded glucose infusion
Fasting glucose levels were similar between the GB and CN groups, and the response to IV glucose administration overlapped until 120 minutes when infusion of the highest dose of glucose, 16 mg/ kg/min, was started ( Figure 1A ). At this point, the glucose curves for the 2 groups diverged and the glycaemic peak was higher in surgical subjects, although the AUC glucose for the step-up portion of the study did not differ (Table 2) . During the descending phase of glucose infusion, GB subjects had higher nadir glucose concentrations (GB:
3.5 AE 0.2, CN: 2.8 AE 0.1 mmol/L; P = .04), and they reached this point later than the control subjects. Over the course of the infusion protocol the overall glucose response (AUC Glucose (40,280 min) ) was significantly higher in the GB subjects ( Figure 1A ) ( Table 2 ).
| β-cell responses to glucose infusion
Despite matching for age, BMI and body fat mass, the surgical subjects had significantly lower fasting insulin and ISR compared to the control subjects ( Table 2 ). The integrated β-cell responses to increasing blood glucose, reflected as the AUC Insulin(40,160 min) and AUC ISR (40,160 min) , were significantly lower in the GB group compared to the non-surgical control group (Figures 1B,C; Table 2 ). During the stepdown in the glucose ramp, insulin concentrations were also lower in the surgical group compared to the control group despite higher glucose levels ( Figure 1C ), while ISR in the 2 groups became more alike ( Figure 1B) . As a result, AUC Insulin(40,280 min) was lower in GB subjects, while the integrated insulin secretory response, AUC ISR(40,280 min) , did not differ statistically from CN (Table 2 ). However, overall insulin secretion, corrected for the ambient glucose concentration, was significantly reduced after GB (AUC ISR(40,280 min) /AUC Glucose (40,280 min) ):
42 AE 5 in GB vs 90 AE 7 in CN; P = .0001).
β-cell sensitivity to glucose, measured as the average of the slopes of ISR:glucose for each subject, was significantly lower in GB subjects during both ascending (GB: 34 AE 6, CN: 82 AE 9 pmol min -1 mM -1 L; P < .0001) and descending phases (GB: 31 AE 6, CN:
74 AE 9 pmol min -1 mM -1 L; P < .0001) of the glucose ramp ( Figures 2A,B and 3B).
Subjects in both groups had higher insulin secretion rates per level of glucose during the step-down compared to the step-up phase ( Figure 3A ). However, this difference, measured as the area inside the ascending and descending ISR:glucose response, was nearly twice as large in GB subjects compared to non-operated individuals (1211 vs 868 pmol/min of ISR × mmol/L of glucose, Figure 3A ).
| Insulin sensitivity, glucose effectiveness and insulin clearance
The insulin sensitivity index (S I ) calculated from insulin and glucose concentrations using the minimal model was not significantly different between the 2 groups (GB: 4.6 AE 1. Among all subjects, there were no significant associations between β-cell glucose sensitivity, taken as the ISR:glucose slope up, and BMI, fasting glucose or insulin sensitivity. Moreover, β-cell glucose sensitivity in GB subjects was not correlated with amount of weight loss or time since surgery. This parameter was also not Data are presented as mean AE SEM unless specified otherwise.
affected by prior history of diabetes in the single subject in the GB group whose β-cell sensitivity to glucose was the highest value among the GB subjects ( Figure 3B ).
| DISCUSSION
The hyperinsulinaemia that accompanies rapid rates of prandial glucose appearance and clearance in GB patients has been taken as evidence that surgery enhances β-cell function. In fact, previous studies implicate increased incretin stimulation, 12, 13 as well as greater β-cell glucose responsiveness after eating, 7,14-16 to explain higher rates of insulin secretion. The findings presented here support a dramatically different model of surgical effects on insulin secretion. In nondiabetic subjects studied several years after GB surgery, β-cell sensitivity to glucose in the absence of enteroinsular axis activity is substantially reduced compared to a well-matched non-surgical control group, suggesting that surgical effects on the β-cell response to glucose occur, but not in the direction predicted by previous work. A plausible explanation for these findings is that dampening the insulin response to glucose is necessary to maintain homeostasis in the face of the rapid surges of nutrient and enteral β-cell stimuli that occur with each meal in GB patients.
We used a direct method of assessing β-cell sensitivity to glucose, applying a well-established and validated protocol, 19,24-28 infusing IV glucose in the fasting state, to eliminate confounding from the high rates of appearance of intestinal glucose and incretin secretion that accompany meal ingestion in GB. The up-and-down ramp provides a broad assessment of the insulin:glucose dose-response across a wide range of glycaemia, as well as a hysteresis pattern, first proposed by Breda et al. 27 and later by Mari and Ferrannini, 29 to describe insulin secretion with rising and falling blood glucose. While our study used a cross-sectional design rather than a prospective pre-and post-surgical comparison, our analysis is not confounded by 
Step-up (0,160 minutes) 33.5 AE 5.5 81.6 AE 8.5**
Step A, β-cell sensitivity to glucose across the entire study in GB (closed circle) and CN (open circle) subjects and B, individual slopes of the 12 GB and 7 CN subjects during the increasing (up) and decreasing (dwn) glucose infusion. Solid arrow shows the ascending phase of glucose ramp, and hollow arrow the declining glucose phase. **P < .001 compared with GB. Data are presented as mean AE SEM the effects of massive changes in body weight and insulin sensitivity that occur in most subjects having had GB. Insulin sensitivity, measured using the method used previously during graded up & down glucose infusion studies, was similar in the surgical and non-surgical groups. 19 The major finding reported here, reduced β-cell glucose sensitivity and relative glucose intolerance in GB subjects, was independent of insulin sensitivity, and was evident acutely as glycaemic stimulation increased. The difference in blood glucose between GB and CN subjects was most evident with the highest rate of glucose infusion (16 mg/kg/min from 120-160 minutes), but insulin and ISR values diverged even earlier in the study, suggesting that the blunted β-cell response was the proximal factor, especially for the ascending phase.
Besides the reduced ISR slope up in GB subjects, decreased β-cell glucose sensing is also supported by the flatter slope down of ISR as glucose levels wane, and the greater difference in ISR between the ramp-up and ramp-down phases (hysteresis effect 27 ). There has been a previous study of β-cell glucose sensitivity in non-diabetic GB subjects that also used a graded glucose infusion, but the authors did not observe differences compared to controls. 28 In that previous experiment, a lower, more gradual glucose ramp was applied, which may have limited the capability to resolve differences such as those seen in our subjects. However, it is notable that the previously reported GB subjects tended to have a flatter ISR:glucose slope and slightly greater glycaemic levels in response to IV glucose. Applying the upand-down protocol to GB subjects and a well-matched CN group, we noted slopes that were 50% to 60% less after surgery, and were consistent enough within groups to be highly significant, even with the modest number of subjects evaluated. Therefore, although this was a cross-sectional comparison, the results suggest that the GB procedure causes a significant change to a fundamental property of β-cells.
Previously published work, 7,30,31 including our own, 11 using ingestion of meals or glucose to stimulate insulin secretion, contrasts with the results presented here. In general, results based on meal studies support stable or increased β-cell glucose sensitivity in nondiabetic subjects after GB, along with improved insulin sensitivity. 7, 30, 31 However, these findings can be challenged because of the complexity of postprandial stimuli after surgery. We and other investigators have previously used IV glucose tolerance tests [5] [6] [7] [8] [32] [33] [34] [35] or hyperglycaemic clamps, 13, 36 to assess the impact of GB on β-cell response to glycaemia. These studies have generally concluded that insulin response to IV glucose administration after surgery is stable, or improved, when adjusted for changes in insulin sensitivity. While the relationship between glucose-stimulated insulin secretion and insulin sensitivity has been long recognized, the association between the 2 parameters has been described only when the acute insulin response to glucose ingestion, or IV boluses of glucose, is measured. 37 Notably, β-cell glucose sensitivity does not vary as a function of insulin sensitivity. 29 Moreover, since the graded glucose protocol captures insulin secretion in response to glucose alone, the attenuated response in GB subjects is probably explained by a β-cellautonomous adaptation to surgery.
The 2 obvious questions that arise when considering these results is how they fit with the unequivocal hyperinsulinaemia of GB subjects in the first 60 to 90 minutes after eating, and why attenuation of β-cell glucose sensitivity would occur after surgery?
While our data do not answer these questions directly, we believe they are related, and can offer a speculation that at least gives some context to our observation.
It is clear that after GB enteral glucose flux is changed dramatically, with estimates that gastric delivery to the intestine is increased up to 25-fold, 9 and the appearance of meal glucose is increased proportionately. 10, 38, 39 In addition, meal-stimulated GLP-1 is enhanced up to 20-fold. 10, 11 In the face of such extraordinary stimulation by circulating factors, postprandial hyperinsulinaemia is not surprising, even with a decrease in β-cell glucose sensitivity to 50% or less of normal, as we show here. In fact, in a previous report in 10 nondiabetic patients after GB, normalizing the rate of nutrient delivery to the gut by administration of continuous infusion of 50-g glucose solution directly into the Roux-limb over 50 minutes (4 kcal/min) compared to 50-g glucose ingestion over 3 minutes (~70 kcal/min) caused deterioration in glucose tolerance as a direct result of the 50% reduction in β-cell sensitivity to glucose (insulin:glucose slope). 9 Also, we previously reported a study of a single subject with GB who underwent insulin secretion measurment after meal ingestion, with passage through the gastric pouch into the jejunum, or after feeding by tube through the remnant stomach, with passage through the pylorus into the duodenum. In this subject, meal appearance and β-cell glucose sensitivity was reduced by 30% with meal administration through gastrostomy compared to oral ingestion. 40 These observations are consistent with our current findings and interpretation in that, once exaggerated enteral stimulation is removed, β-cell function after GB is blunted.
A corollary to this argument is that, if β-cell glucose sensitivity was not reduced, GB patients might have difficulty preventing significant drops in post-absorptive glycaemia. Indeed, we have noted previously that GB subjects with the postprandial hypoglycaemia syndrome had greater hysteresis effects, 38 consistent with reduced β-cell sensitivity to declining glucose levels, 27 as compared to asymptomatic individuals after GB or non-operated controls. We hypothesize that, following GB, the β-cell adapts to mitigate excessive stimulation from the large surges of prandial secretagogues, and that individuals who do not make this adaptation develop hypoglycaemia.
A second major finding from this study, and one that is also consistent with an adaptation to protect against hypoglycaemia, is the reduction of glucose effectiveness after GB. A reduction of insulinindependent glucose disposal has been demonstrated previously in GB subjects studied with IV glucose tolerance tests. 8 In this report, diminished S G was observed only in individuals with normal glucose tolerance, as opposed to those with preoperative impaired glucose tolerance or type 2 diabetes. Also, reduction in S G occurred as early as 1 week after surgery and persisted for 3 months, suggesting that this change was not dependent on weight loss. 8 By contrast, a comparable amount of weight loss after dietary caloric restriction does not change glucose effectiveness. 41 It is also notable that individuals with post-GB hypoglycaemia have higher S G during IV glucose tolerance tests than unaffected GB subjects. 42 Taken together, these findings suggest the hypothesis that reduction in S G is part of general adaptation of glucose metabolism to prevent hypoglycaemia after GB.
There are several limitations to our study that merit discussion.
First, the sample size involved in this set of experiments is small and may not be reflective of the greater population of patients with GB. However, the GB group had the female predominance generally found in bariatric surgery cohorts, and there were not substantial effects of time since surgery or of weight loss on insulin secretion.
Moreover, the effect size between the 2 groups was substantial, with very little overlap in the parameters of insulin secretion. The crosssectional design of the study is a second potential weakness, as much of the groundbreaking work in the area of bariatric surgery is based on comparison of subjects before and after surgery. [1] [2] [3] [4] [5] However, the benefit of within-subject designs is mitigated for interventions such as GB that cause huge changes to metabolic physiology. Thus, for isolating a simple physiologic parameter, that is, β-cell sensitivity to glucose, there are advantages to well-matched cross-sectional cohorts.
Finally, we did not perform meal tests in our cohort of patients without GB; therefore, we cannot directly compare results from graded glucose infusion to insulin secretion during enteral stimulation between the 2 groups. While this limits some of our interpretations, the disparity between previous work, showing stable or enhanced insulin secretion in GB subjects after eating, and the current results, demonstrating a marked reduction in β-cell glucose sensitivity, is stark.
In summary, individuals with GB for 2 to 11 years who have received a fixed glucose infusion have reduced insulin responses and relative hyperglycaemia. This blunted β-cell glucose sensitivity is independent of insulin sensitivity and was very consistent across our group of GB subjects. The change in a fundamental characteristic of β-cell function, the insulin response to glucose, in GB subjects with normal fasting glucose and HbA1c suggests an adaptation of β-cell function to surgery that accommodates glucose homeostasis to changes in GI nutrient flux. The parallel reduction of S G could serve a similar function. These hypotheses require further study, but provide a novel perspective on glucose metabolism following gastric bypass surgery.
